BlockBeats News, January 11th, Hsiao-Wei Wang, Co-Executive Director of the Ethereum Foundation, stated that Ethereum is steadily moving towards a future where zero-knowledge cryptography becomes a core part of the network, with years of research now converging with real-world progress. Zero-knowledge proofs are part of Ethereum's mid-term roadmap and have seen several breakthroughs in the past year or two. While the current focus of upgrades is still on improving Layer 2 network execution and Blob space, zero-knowledge proofs as a protocol-level feature have become increasingly feasible.
Furthermore, Ethereum researchers have released the native zkEVM plan, allowing the network to default to using zero-knowledge proofs to verify transactions. This technology can significantly reduce the computational work required to secure Ethereum, enabling scalability without sacrificing decentralization or reliability. Hsiao-Wei Wang emphasized that even as the network continues to evolve, Ethereum's core principles of resilience, security, censorship resistance, and neutrality remain.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.





Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.










Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.